Bile acid receptor 3D structures - Revision history

Joel L. Sussman at 19:20, 11 March 2023

Joel L. Sussman — Sat, 11 Mar 2023 19:20:57 GMT

←Older revision		Revision as of 19:20, 11 March 2023
Line 24:		Line 24:
	*hFXR LBD complex with nuclear receptor corepressor 2		*hFXR LBD complex with nuclear receptor corepressor 2

-	**[[5iaw]], [[6hl0~~]], [[6hl1~~]] - hFXR LBD + NCOA2 peptide<br />	+	**[[5iaw]], [[6hl0]] - hFXR LBD + NCOA2 peptide<br />
	**[[1osv]] – hFXR LBD + CDC derivative + NCOA2 peptide<br />		**[[1osv]] – hFXR LBD + CDC derivative + NCOA2 peptide<br />
	**[[5z12]] - hFXR LBD (mutant) + indole derivative + NCOA2 peptide + RXR-a + retinoic acid<br />		**[[5z12]] - hFXR LBD (mutant) + indole derivative + NCOA2 peptide + RXR-a + retinoic acid<br />
-	**[[~~4qe6~~]] – hFXR LBD + CDC + NCOA2 peptide<br />	+	**[[6hl1]] – hFXR LBD + CDC + NCOA2 peptide<br />
	**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br />		**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br />
	**[[5y1j]], [[7d42]], [[7vue]] – hFXR LBD + drug + NCOA2 peptide<br />		**[[5y1j]], [[7d42]], [[7vue]] – hFXR LBD + drug + NCOA2 peptide<br />

Michal Harel at 09:31, 3 November 2022

Michal Harel — Thu, 03 Nov 2022 09:31:52 GMT

←Older revision		Revision as of 09:31, 3 November 2022
Line 29:		Line 29:
	**[[4qe6]] – hFXR LBD + CDC + NCOA2 peptide<br />		**[[4qe6]] – hFXR LBD + CDC + NCOA2 peptide<br />
	**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br />		**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br />
-	**[[5y1j]], [[7d42]] – hFXR LBD + drug + NCOA2 peptide<br />	+	**[[5y1j]], [[7d42]], [[7vue]] – hFXR LBD + drug + NCOA2 peptide<br />
	**[[5y49]] – hFXR LBD + moderator + NCOA2 peptide<br />		**[[5y49]] – hFXR LBD + moderator + NCOA2 peptide<br />
	**[[5yxb]], [[5yxd]], [[5yxj]], [[5yxl]] – hFXR LBD + pyridine derivative + NCOA2 peptide<br />		**[[5yxb]], [[5yxd]], [[5yxj]], [[5yxl]] – hFXR LBD + pyridine derivative + NCOA2 peptide<br />
		+	**[[7trb]] – hFXR LBD + inhibitor + NCOA2 peptide<br />
	**[[4qe8]] – hFXR LBD + DM175 + NCOA2 peptide<br />		**[[4qe8]] – hFXR LBD + DM175 + NCOA2 peptide<br />
	}}		}}

	[[Category:Topic Page]]		[[Category:Topic Page]]

Michal Harel at 09:17, 12 May 2021

Michal Harel — Wed, 12 May 2021 09:17:38 GMT

←Older revision		Revision as of 09:17, 12 May 2021
Line 10:		Line 10:
	**[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]], [[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br />		**[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]], [[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br />
	**[[4oiv]] – hFXR LBD + antagonist <br />		**[[4oiv]] – hFXR LBD + antagonist <br />
-

	*hFXR LBD complex with nuclear receptor corepressor 1		*hFXR LBD complex with nuclear receptor corepressor 1
Line 30:		Line 29:
	**[[4qe6]] – hFXR LBD + CDC + NCOA2 peptide<br />		**[[4qe6]] – hFXR LBD + CDC + NCOA2 peptide<br />
	**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br />		**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide<br />
-	**[[5y1j]] – hFXR LBD + drug + NCOA2 peptide<br />	+	**[[5y1j]], [[7d42]] – hFXR LBD + drug + NCOA2 peptide<br />
	**[[5y49]] – hFXR LBD + moderator + NCOA2 peptide<br />		**[[5y49]] – hFXR LBD + moderator + NCOA2 peptide<br />
	**[[5yxb]], [[5yxd]], [[5yxj]], [[5yxl]] – hFXR LBD + pyridine derivative + NCOA2 peptide<br />		**[[5yxb]], [[5yxd]], [[5yxj]], [[5yxl]] – hFXR LBD + pyridine derivative + NCOA2 peptide<br />

Michal Harel at 09:13, 25 June 2020

Michal Harel — Thu, 25 Jun 2020 09:13:08 GMT

Michal Harel at 08:45, 15 April 2019

Michal Harel — Mon, 15 Apr 2019 08:45:26 GMT

←Older revision		Revision as of 08:45, 15 April 2019
Line 9:		Line 9:
	**[[5q0i]] – hFXR LBD + PPAR gamma coactivator peptide<br />		**[[5q0i]] – hFXR LBD + PPAR gamma coactivator peptide<br />
	**[[5q15]], [[5wzx]] – hFXR LBD + coactivator SRC peptide<br />		**[[5q15]], [[5wzx]] – hFXR LBD + coactivator SRC peptide<br />
-	**[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]],	+	**[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]], [[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br />
-	[[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br />	+
	**[[4oiv]] – hFXR LBD + antagonist <br />		**[[4oiv]] – hFXR LBD + antagonist <br />

Michal Harel at 08:44, 15 April 2019

Michal Harel — Mon, 15 Apr 2019 08:44:58 GMT

←Older revision		Revision as of 08:44, 15 April 2019
Line 2:		Line 2:

	Updated on {{REVISIONDAY2}}-{{MONTHNAME\|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}		Updated on {{REVISIONDAY2}}-{{MONTHNAME\|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
-		+	{{#tree:id=OrganizedByTopic\|openlevels=0\|

	*hFXR LBD complex		*hFXR LBD complex

Michal Harel at 08:42, 15 April 2019

Michal Harel — Mon, 15 Apr 2019 08:42:53 GMT

←Older revision		Revision as of 08:42, 15 April 2019
Line 36:		Line 36:
	**[[4qe8]] – hFXR LBD + DM175 + NCOA2 peptide<br />		**[[4qe8]] – hFXR LBD + DM175 + NCOA2 peptide<br />
	}}		}}
		+
		+	[[Category:Topic Page]]

Michal Harel at 08:41, 15 April 2019

Michal Harel — Mon, 15 Apr 2019 08:41:55 GMT

←Older revision		Revision as of 08:41, 15 April 2019
Line 1:		Line 1:
		+	==3D structures of bile acid receptor==
		+
		+	Updated on {{REVISIONDAY2}}-{{MONTHNAME\|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
		+
		+
	*hFXR LBD complex		*hFXR LBD complex

Michal Harel: New page: *hFXR LBD complex 1osh, 3fli, 3l1b – hFXR LBD + non-steroidal agonist - human
5q0i – hFXR LBD + PPAR gamma coactivator peptide
**5q15, 5wzx ...

Michal Harel — Mon, 15 Apr 2019 08:40:25 GMT

New page: *hFXR LBD complex **1osh, 3fli, 3l1b – hFXR LBD + non-steroidal agonist - human **5q0i – hFXR LBD + PPAR gamma coactivator peptide **5q15, 5wzx ...

New page

*hFXR LBD complex

**[[1osh]], [[3fli]], [[3l1b]] – hFXR LBD + non-steroidal agonist - human 
**[[5q0i]] – hFXR LBD + PPAR gamma coactivator peptide 
**[[5q15]], [[5wzx]] – hFXR LBD + coactivator SRC peptide 
**[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]],
[[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide 
**[[4oiv]] – hFXR LBD + antagonist 

*hFXR LBD complex with nuclear receptor corepressor 1

**[[4wvd]] - hFXR LBD + NCOA1 peptide 
**[[3bej]], [[3dct]], [[3dcu]], [[3hc5]], [[3hc6]], [[3rut]], [[3ruu]], [[3rvf]] – hFXR LBD + non-steroidal agonist + NCOA1 peptide 
**[[6a5w]] - hFXR LBD + thiazole derivative + NCOA1 peptide 
**[[6a5x]] - hFXR LBD (mutant) + thiazole derivative + NCOA1 peptide 
**[[5y44]] – hFXR LBD + moderator + NCOA1 peptide 
**[[6a5y]], [[6a5z]] - hFXR LBD (mutant) + thiazole derivative + NCOA1 peptide + RXR-a + retinoic acid 
**[[6a60]] - hFXR LBD (mutant) + isoxazole derivative + NCOA1 peptide + RXR-a + retinoic acid 
**[[3oof]], [[3ook]], [[3p88]], [[3p89]] – hFXR LBD (mutant) + non-steroidal agonist + NCOA1 peptide 

*hFXR LBD complex with nuclear receptor corepressor 2

**[[1osv]] – hFXR LBD + CDC derivative + NCOA2 peptide 
**[[5z12]] - hFXR LBD (mutant) + indole derivative + NCOA2 peptide + RXR-a + retinoic acid 
**[[4qe6]] – hFXR LBD + CDC + NCOA2 peptide 
**[[5ick]] – hFXR LBD + feroline + NCOA2 peptide 
**[[5y1j]] – hFXR LBD + drug + NCOA2 peptide 
**[[5y49]] – hFXR LBD + moderator + NCOA2 peptide 
**[[5yxb]], [[5yxd]], [[5yxj]], [[5yxl]] – hFXR LBD + pyridine derivative + NCOA2 peptide 
**[[4qe8]] – hFXR LBD + DM175 + NCOA2 peptide 
}}

←Older revision		Revision as of 09:13, 25 June 2020
Line 4:		Line 4:
	{{#tree:id=OrganizedByTopic\|openlevels=0\|		{{#tree:id=OrganizedByTopic\|openlevels=0\|

-	*hFXR LBD complex	+	*hFXR LBD residues 245-486 complex

	**[[1osh]], [[3fli]], [[3l1b]] – hFXR LBD + non-steroidal agonist - human <br />		**[[1osh]], [[3fli]], [[3l1b]] – hFXR LBD + non-steroidal agonist - human <br />
	**[[5q0i]] – hFXR LBD + PPAR gamma coactivator peptide<br />		**[[5q0i]] – hFXR LBD + PPAR gamma coactivator peptide<br />
-	**[[5q15]], [[5wzx]] – hFXR LBD + coactivator SRC peptide<br />
	**[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]], [[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br />		**[[3fxv]], [[3gd2]], [[3okh]], [[3oki]], [[3olf]], [[3omk]], [[3omm]], [[1ot7]] – hFXR LBD + CDC derivative + RPGR-interacting protein peptide<br />
	**[[4oiv]] – hFXR LBD + antagonist <br />		**[[4oiv]] – hFXR LBD + antagonist <br />
Line 15:		Line 14:
	*hFXR LBD complex with nuclear receptor corepressor 1		*hFXR LBD complex with nuclear receptor corepressor 1

-	**[[4wvd]] - hFXR LBD + NCOA1 peptide<br />	+	**[[4wvd]], [[5q0w]], [[5q15]], [[5wzx]], [[5q0j]], [[5q0k]], [[5q0l]], [[5q0m]], [[5q0n]], [[5q0o]], [[5q0p]], [[5q0q]], [[5q0r]], [[5q0s]], [[5q0t]], [[5q0u]], [[5q0v]], [[5q0x]], [[5q0y]], [[5q0z]], [[5q10]], [[5q11]], [[5q12]], [[5q13]], [[5q14]], [[5q16]], [[5q17]], [[5q18]], [[5q19]], [[5q1a]], [[5q1b]], [[5q1c]], [[5q1d]], [[5q1e]], [[5q1f]], [[5q1g]], [[5q1h]], [[5q1i]] - hFXR LBD + NCOA1 peptide<br />
-	**[[3bej]], [[3dct]], [[3dcu]], [[3hc5]], [[3hc6]], [[3rut]], [[3ruu]], [[3rvf]] – hFXR LBD + non-steroidal agonist + NCOA1 peptide<br />	+	**[[3bej]], [[3dct]], [[3dcu]], [[3hc5]], [[3hc6]], [[3rut]], [[3ruu]], [[3rvf]], [[6itm]] – hFXR LBD + non-steroidal agonist + NCOA1 peptide<br />
	**[[6a5w]] - hFXR LBD + thiazole derivative + NCOA1 peptide<br />		**[[6a5w]] - hFXR LBD + thiazole derivative + NCOA1 peptide<br />
	**[[6a5x]] - hFXR LBD (mutant) + thiazole derivative + NCOA1 peptide<br />		**[[6a5x]] - hFXR LBD (mutant) + thiazole derivative + NCOA1 peptide<br />
Line 26:		Line 25:
	*hFXR LBD complex with nuclear receptor corepressor 2		*hFXR LBD complex with nuclear receptor corepressor 2

		+	**[[5iaw]], [[6hl0]], [[6hl1]] - hFXR LBD + NCOA2 peptide<br />
	**[[1osv]] – hFXR LBD + CDC derivative + NCOA2 peptide<br />		**[[1osv]] – hFXR LBD + CDC derivative + NCOA2 peptide<br />
	**[[5z12]] - hFXR LBD (mutant) + indole derivative + NCOA2 peptide + RXR-a + retinoic acid<br />		**[[5z12]] - hFXR LBD (mutant) + indole derivative + NCOA2 peptide + RXR-a + retinoic acid<br />